These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23399677)

  • 1. [A double-blind comparative study to evaluate the efficacy and safety of NerBloc® (rimabotulinumtoxinB) administered in a single dose to patients with cervical dystonia].
    Kaji R; Shimizu H; Takase T; Osawa M; Yanagisawa N
    Brain Nerve; 2013 Feb; 65(2):203-11. PubMed ID: 23399677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
    Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
    Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
    Lew MF; Brashear A; Factor S
    Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
    Quagliato EM; Carelli EF; Viana MA
    Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
    Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia.
    Chinnapongse R; Pappert EJ; Evatt M; Freeman A; Birmingham W
    Int J Neurosci; 2010 Nov; 120(11):703-10. PubMed ID: 20942584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.
    Lew MF; Adornato BT; Duane DD; Dykstra DD; Factor SA; Massey JM; Brin MF; Jankovic J; Rodnitzky RL; Singer C; Swenson MR; Tarsy D; Murray JJ; Koller M; Wallace JD
    Neurology; 1997 Sep; 49(3):701-7. PubMed ID: 9305326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies.
    Lew MF; Chinnapongse R; Zhang Y; Corliss M
    Int J Neurosci; 2010 Apr; 120(4):298-300. PubMed ID: 20374078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
    Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
    Figgitt DP; Noble S
    Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type B for cervical dystonia.
    Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
    Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
    J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.